ArticleBiosensors2024
Label-Free Surface-Enhanced Raman Spectroscopy with Machine Learning for the Diagnosis of Thyroid Cancer by Using Fine-Needle Aspiration Liquid Samples.
Article in Biosensors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Leakage-Free Benchmarking of Electronic Noses for Beef Freshness: A Signal-Richness Criterion for Model Selection.Foods (Basel, Switzerland) · 2026Article
- Tertiary Lymphoid Structures as Predictors of Recurrence in Colorectal Cancer: Development and Validation of a Machine Learning-Based Scoring Model.Cancer medicine · 2026Article
- Portable Multispectral Optoelectronic System for Thyroid Cancer Detection.Sensors (Basel, Switzerland) · 2026Article
- Plasmonic and surface-enhanced Raman nanobiosensors for quantitative molecular detection.Discover nano · 2026Review
- Multimodal diagnostic network integrating infrared and mass spectra for lung cancer.Biomedical optics express · 2026Article
- Label-free molecular profiling of cancer using Raman spectroscopy: from fundamentals to clinical applications.Frontiers in oncology · 2026Review
- Emerging liquid biopsy markers in thyroid cancer: from isolation technologies to clinical translation.Frontiers in endocrinology · 2026Review
- Predictive value of label-free surface-enhanced Raman spectroscopy for locally advanced gastric cancer following neoadjuvant chemoimmunotherapy.Frontiers in immunology · 2025Article
- Research progress on artificial intelligence technology-assisted diagnosis of thyroid diseases.Frontiers in oncology · 2025Review
- Recent advances in applications of artificial intelligence-assisted Raman spectroscopy in diagnosis of cancers.Frontiers in molecular biosciences · 2025Review
- An Integrative Framework for Healthcare Recommendation Systems: Leveraging the Linear Discriminant Wolf-Convolutional Neural Network (LDW-CNN) Model.Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The incidence of thyroid cancer is increasing worldwide. Fine-needle aspiration (FNA) cytology is widely applied with the use of extracted biological cell samples, but current FNA cytology is labor-intensive, time-consuming, and can lead to the risk of false-negative results. Surface-enhanced Raman spectroscopy (SERS) combined with machine learning algorithms holds promise for cancer diagnosis. In this study, we develop a label-free SERS liquid biopsy method with machine learning for the rapid and accurate diagnosis of thyroid cancer by using thyroid FNA washout fluids. These liquid supernatants are mixed with silver nanoparticle colloids, and dispersed in quartz capillary for SERS measurements to discriminate between healthy and malignant samples. We collect Raman spectra of 36 thyroid FNA samples (18 malignant and 18 benign) and compare four classification models: Principal Component Analysis-Linear Discriminant Analysis (PCA-LDA), Random Forest (RF), Support Vector Machine (SVM), and Convolutional Neural Network (CNN). The results show that the CNN algorithm is the most precise, with a high accuracy of 88.1%, sensitivity of 87.8%, and the area under the receiver operating characteristic curve of 0.953. Our approach is simple, convenient, and cost-effective. This study indicates that label-free SERS liquid biopsy assisted by deep learning models holds great promise for the early detection and screening of thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.